Vor Biopharma Incorporated develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.VOR33 is in phase 1/2 trials to treat acute myeloid leukemia and other blood cancers. Vor Biopharma was incorporated in 2015 and is headquartered in Cambridge, MA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$7.59 | A | |
$3.58 | A | |
$46.15 | A |